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Abstract
Background: The major histocompatibility complex (MHC) is the most important genomic region that contributes to the
risk of graft versus host disease (GVHD) after haematopoietic stem cell transplantation. Matching of MHC class I and II genes
is essential for the success of transplantation. However, the MHC contains additional genes that also contribute to the risk of
developing acute GVHD. It is difficult to identify these genes by genetic association studies alone due to linkage
disequilibrium in this region. Therefore, we aimed to identify MHC genes and other genes involved in the pathophysiology
of GVHD by mRNA expression profiling.
Methodology/Principal Findings: To reduce the complexity of the task, we used genetically well-defined rat inbred strains
and a rat skin explant assay, an in-vitro-model of the graft versus host reaction (GVHR), to analyze the expression of MHC,
natural killer complex (NKC), and other genes in cutaneous GVHR. We observed a statistically significant and strong up or
down regulation of 11 MHC, 6 NKC, and 168 genes encoded in other genomic regions, i.e. 4.9%, 14.0%, and 2.6% of the
tested genes respectively. The regulation of 7 selected MHC and 3 NKC genes was confirmed by quantitative real-time PCR
and in independent skin explant assays. In addition, similar regulations of most of the selected genes were observed in
GVHD-affected skin lesions of transplanted rats and in human skin explant assays.
Conclusions/Significance: We identified rat and human MHC and NKC genes that are regulated during GVHR in skin explant
assays and could therefore serve as biomarkers for GVHD. Several of the respective human genes, including HLA-DMB, C2,
AIF1, SPR1, UBD, and OLR1, are polymorphic. These candidates may therefore contribute to the genetic risk of GVHD in
patients.
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Introduction
Haematopoietic stem cell transplantation (HSCT) is currently
the only potentially curative treatment for many malignant and
non-malignant haematological diseases. However, the overall
survival rate after transplantation is still only 40% to 60% due
to severe posttransplant complications [1], which include graft
versus host disease (GVHD), relapse, and infection. Human
leukocyte antigen (HLA) matching is essential to reduce the risk of
graft rejection and GVHD [2]. However, non-HLA genes also
impact on transplant outcome [3] and acute GVHD can be fatal
even in patients receiving transplants from HLA-identical matched
sibling donors (MSD). The cumulative incidence of grade II to IV
GVHD was 35% in a recent study evaluating 1960 MSD
transplants [4]. MSDs are currently available for about one third
of the patients and, therefore, alternative donors are needed.
HLA-matched unrelated donors (MUD) are more readily accepted
than cord blood or mismatched related donors.
The level of HLA matching used for selection of MUDs has
changed over time and usually includes now HLA-A, B, C, and
DRB1 loci (8/8 match). In some studies matching has been
extended to the HLA-DQB1 locus (10/10 match). A large recent
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study has compared MSD and 8/8 matched MUD transplants in a
homogenous cohort of patients with chronic myeloid leukemia and
found a 2.44 times higher risk of grade II to IV acute GVHD in 8/
8 matched MUD compared to MSD transplants [5]. In another
study, the incidence of grade II to IV acute GVHD was still higher
in 10/10 matched MUD compared to MSD transplants [6]. The
higher risk of GVHD after MUD compared to MSD transplants
could be due to a higher degree of similarity in non-HLA genes for
siblings, who share 50% of their genome with the respective
recipient. However, also the HLA region itself could contribute to
this difference since it harbors, in addition to the classical HLA
class I and II genes, more than 200 other genes [7], many with
immunological functions. In accordance with this hypothesis,
mismatching of microsatellite markers in HLA class I, class II, and
class III regions was associated with an increased risk of death in
10/10 matched MUD transplants [8]. The HLA complex, as is the
whole human genome, is organized into segments of closely linked
genetic variants that are inherited as haplotypes on the same DNA
strand [9]. HLA haplotypes can be defined by HLA class I and II
alleles and they are in strong linkage disequilibrium with defined
genetic variants of non-class I/non-class II genes within the
haplotype blocks within this region [10,11]. However, a given
HLA allele can occur in the context of different HLA haplotypes
in MUDs. Interestingly, HLA haplotype mismatching in 10/10
matched MUD transplants was associated with an increased risk of
severe acute GVHD [12]. This finding demonstrates that the HLA
complex encodes in addition to HLA-A, B, C, DRB1, and DQB1
further unidentified genes that contribute significantly to the risk of
developing acute GVHD. In case of disparity between donor and
recipient alleles these genes may function as minor histocompat-
ibility antigens. Alternatively, specific allelic variants may also
increase the risk of GVHD, e.g., TNFA, a gene located within the
class III region of the MHC encoding the pro-inflammatory
cytokine tumor necrosis factor alpha (TNF-a.) Several TNFA
polymorphisms have been associated with an increased risk of
GVHD and some of them are associated with increased TNF-a
levels [13]. The strong linkage disequilibrium within the HLA
complex makes it very difficult to identify further non-class I/non-
class II HLA genes involved in the pathophysiology of GVHD by
genetic association studies alone.
HLA gene expression profiling may be an alternative strategy to
identify HLA genes that are involved in the pathophysiology of
GVHD. We assumed that at least some non-class I/non-class II
HLA genes that contribute to the risk of GVHD change their
expression levels during disease progression. However, the genetic
variation between clinical samples complicates the situation
because allelic variation of gene expression could interfere with
expression change in the pathophysiological process. Therefore,
we decided to analyze a rat model of GVHD making use of
genetically well-defined inbred strains. Importantly, the non-class
I/non-class II genes of human (HLA) and rat (RT1) MHCs are
highly conserved [14,15,16]. However, the size and organization
of MHC class I encoding regions are considerably variable and the
rat possesses a significant number of MHC class Ib genes for which
no human homologues exist [15]. At least some of these genes
have already been proven to encode ligands for inhibitory or
activating natural killer (NK) receptors [17,18]. In the rat, in
contrast to human, NK receptors of the Ly49 killer cell lectin-like
receptor type predominate over killer cell Ig-like receptor genes
[19]. Therefore, we also included the natural killer complex
(NKC) in the expression profiling which harbors the Ly49 genes
and additional natural cytotoxicity receptor genes.
To reduce the complexity of the experimental approach, we
used an in-vitro-model of the graft versus host reaction (GVHR) –
the skin explant assay. This assay has been shown to be a sensitive
predictor of GVHD in patients [20]. It was also used to study the
pathophysiology of GVHR [21]. Recently, we developed a rat skin
explant assay [22]. This standardized in-vitro-model allows the
study of gene expression during GVHR in a setting that is not
influenced by undefined genetic differences between tissue samples
which is unavoidable in human studies. In the present study we
used this model to analyze the MHC and NKC gene expression
profiles of GVHR.
Results
GVHR in rat skin explant assays
To obtain skin explant samples for an expression profiling
experiment, we used BN rats (RT1n) as recipients and PVG rats
(RT1c) as donors. This combination is mismatched for minor and
major histocompatibility antigens, which gives rise to GVHR
grades I to IV [22]. PVG splenocytes were stimulated for 7 days in
a mixed lymphocyte reaction (MLR) with irradiated BN
splenocytes. Syngeneic co-cultures (BN plus irradiated BN
splenocytes) were performed as control experiments. The
stimulation index indicated a specific proliferation of PVG
lymphocytes in response to irradiated BN lymphocytes in contrast
to syngeneic cultures of BN lymphocytes (p,0.0001, U test; n = 12
responder animals per strain, data not shown). After 7 days the
PVG and BN lymphocytes were harvested, added to fresh BN skin
samples from 12 individual animals and cultured for 3 further
days. For further controls, additional BN skin samples from the
same animals were cultured in medium only. On day 3 the skin
samples were harvested and snap frozen for RNA preparation.
Parallel samples were fixed and assayed for histological evidence of
GVHR (Fig. 1). Co-culture of BN skin explants with pre-
stimulated allogeneic PVG lymphocytes resulted in higher grade
GVHR than co-culture with BN lymphocytes (p = 0.0336; U test).
As in a previous experimental series [22], the syngeneic
lymphocyte co-culture more frequently resulted in GVHR-like
pathology of grade II or higher than culture of the skin explants in
medium only.
Figure 1. Induction of a GVHR in BN rat skin explants exposed
to PVG lymphocytes. A summary of the histological GVHR grading of
BN skin samples cultured in medium alone, together with syngeneic BN
lymphocytes, and together with pre-stimulated allogeneic PVG
lymphocytes (n = 12 in each group) is given. The samples represented
by closed circles were used for both gene expression profiling and qRT-
PCR experiments, whereas the other samples were only used for gene
expression profiling. The pair-wise comparison (U test) indicated a
significant difference between skin explant cultures with BN and PVG
lymphocytes.
doi:10.1371/journal.pone.0016582.g001
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Expression profiling of GVHR in rat skin explants
RNA was prepared from the 24 BN skin explants exposed either
to syngeneic (BN; n= 12) or to allogeneic (PVG, n= 12)
lymphocytes and used for MHC gene expression profiling. We
designed a custom microarray which contained specific probes for
the 224 MHC genes. For this purpose the annotated sequence of
the MHC of the BN strain was used [16]. For 88 of these genes,
i.e. 39.3%, we had to design custom probes. A list of the MHC
genes in the chromosomal order with all results obtained in the
expression profiling experiment is given in the Table S1a. For 42
of the 224 MHC genes, a probe on the array indicated a
significant regulation (p,0.05) in the allogeneic skin explant assays
(n = 12) compared to the syngeneic controls (n = 12) (Table S1b).
Eleven of these MHC genes showed on average at least a 2-fold
up-regulation (log2-fold change $1) or 50% reduction (log2-fold
change #21) of mRNA levels (Fig. 2A, Table S1c). This
amplitude of change is conventionally considered to be biologically
relevant. Of these genes one was down-regulated (Ly6g6e) while 10
were up-regulated (Fig. 2A). Fourteen further MHC genes were
regulated significantly (p,0.05) but with smaller amplitude
(Table S1c). The regulation of 17 MHC genes appeared to be
more doubtful because less than 50% of the probes for that gene
indicated a significant regulation. Thus, we considered 25 MHC
genes to be significantly regulated in the expression profiling
Figure 2. Expression profiling of BN skin explant samples exposed to allogeneic (PVG) lymphocytes in comparison to those
exposed to syngeneic (BN) lymphocytes. (A) The log2-fold changes in gene expression of significantly regulated MHC genes (p,0.05) are
shown. (B) The log2-fold changes in gene expression of significantly regulated NKC genes (p,0.05) are shown. (C) The log2-fold changes in gene
expression of 168 significantly (p,0.05) and strongly (log2-fold change $1 or #21) regulated non-MHC and non-NKC genes indicate the range of
observed alterations in gene expression levels among the 6342 tested genes. In panels A and B, black bars indicate a strong change (log2-fold change
$1 or #21), dotted bars alterations below this amplitude, and white bars expression changes that were not detected at a significant level with all,
but at least with 50% of the probes present on the array for that gene. When more than one probe indicated a significant change of gene expression
the means and standard deviations of the log2-fold changes are shown (see Tables S1, S2, and S3 for further details).
doi:10.1371/journal.pone.0016582.g002
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experiment (Fig. 2A). These included the classical class Ia genes
RT1-A1 and RT1-A2, 8 non-classical class Ib genes (RT1-CE2,
RT1-CE3, RT1-CE5, RT1-CE8, RT1-CE10, RT1-CE16, RT1-
T24-4, RT-BM1) and 3 genes involved in antigen presentation
(RT1-DMb, Tap1, Psmb8).
Furthermore, 43 genes of the NKC region, as a second
important immune gene cluster, were represented on the array
including all Ly49 genes in this region (Table S2a). For 8 of the 43
NKC genes represented on the array, a probe indicated a
significant regulation (p,0.05) in the allogeneic skin explant assays
compared to the syngeneic controls (Table S2b, S2c). In addition
to the Olr1 gene, 6 Ly49 genes appeared to be up-regulated in the
allogeneic skin explant assays (Fig. 2B). Not all probes for the
Ly49i3 gene indicated a significant up-regulation. However, all
significant results for this gene indicated a strong regulation (log2-
fold change .2). A statistically significant (p,0.05) but only
moderate up-regulation (log2-fold change,1) was detected for the
Ly49i7 gene.
Probes for 6342 additional genes from all chromosomes were
included mainly to allow for data normalization. For 168 of the non-
MHC/non-NKC genes, a probe on the array indicated a significant
(p,0.05) and strong (log2-fold change $1 or #21) regulation in
the allogeneic skin explant assays compared to the syngeneic
controls (Fig. 3C, Table S3). The 20 genes showing the strongest
change in expression levels are shown inTable 1. All 20 genes were
up-regulated and they included several genes with functions clearly
associated with the immune response such as genes encoding
chemokines (Ccl9, Ccl6), Fc receptors (Fcgr3a, Fcgr2b), the proteases
cathepsin S (Ctss) and granzyme C (Gzmc), and the inflammatory
triggering receptor on myeloid cells 2 (Trem2).
The percentage of significantly (p,0.05) and strongly (log2-fold
change $1 or #21) up- or down-regulated genes was higher in
the NKC region (14.0%) compared to MHC region (4.9%) and
the genes encoded in other regions of the genome (2.6%). This
difference was even more pronounced for up-regulated genes.
14.0% of the NKC, but only 4.5% of the MHC and 1.5% of the
other genes were up-regulated (Table 2).
For a general analysis of the gene expression data the PANTHER
system [23] was used. With this tool we found a significant up-
regulation of genes taking part in ‘‘immunity and defence’’
(p,0.0001, binominal test). More specifically, genes involved in
‘‘T cell-mediated immunity’’ (p,0.0001), ‘‘NK cell-mediated
immunity’’ (p,0.0001), ‘‘cytokine and chemokine-mediated signal-
ing’’ (p= 0.0032), and ‘‘B cell and antibody-mediated immunity’’
(p= 0.0235) were up-regulated. Genes involved in ‘‘complement-
mediated immunity’’ (p= 0.0336) and ‘‘cell adhesion‘‘ (p= 0.0003)
were down-regulated (data not shown).
Confirmation of microarray results by quantitative real-
time polymerase chain reaction (qRT-PCR)
To determine the reliability of the microarray results, we
analyzed the expression of 13 selected genes from the MHC and
NKC regions by qRT-PCR experiments in 8 of the sample pairs
that had been used for the microarrays (see Fig. 1). For 12 genes
the regulation that was observed in the microarray experiment was
confirmed by qRT-PCR as indicated by a regulation into the same
direction when the allogeneic and syngeneic skin explant assays
were compared using the DD cycle threshold (ct) method for
relative quantification of gene expression (Fig. 3). Only one gene,
RT1-CE10, was found to be strongly up-regulated in allogeneic
skin explants in the microarray experiment but slightly down-
regulated in qRT-PCR. In the qRT-PCR experiments, we also
included parallel skin explants that were cultured in medium only.
Eight genes (RT1-DMb, Aif1, Lst1, RT1-CE3, Ubd, Olr1, Ly49si1,
Figure 3. Verification of the regulation in gene expression observed in the microarray experiment by qRT-PCR. A subgroup of 8
samples used for the microarray experiment (see Fig. 1) was analyzed by qRT-PCR for the expression of 10 MHC and 3 NKC genes. The DDct value
was calculated, i.e. the Dct (Gapdh – gene of interest) of the allogeneic skin explant samples minus Dct (Gapdh – gene of interest) of the
corresponding control sample. The control sample was either a parallel skin explant exposed to syngeneic lymphocytes as in the microarray
experiment (syngeneic control, black bars) or a parallel skin explant sample cultured in medium only (medium control, white bars). The means of the
DDct values plus standard errors of the mean (SEM) are shown. A positive value indicates an up-regulation of gene expression in the allogeneic
samples.
doi:10.1371/journal.pone.0016582.g003
MHC Genes and Risk of Graft versus Host Disease
PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e16582
and Ly49i9) showed an up-regulation in the allogeneic skin explant
assay also in this comparison (Fig. 3). Six of these genes (Aif1, Lst1,
Ubd, Olr1, Ly49si1, and Ly49i9) were clearly found to be up-
regulated in both comparisons.
The up-regulation of genes in skin explants could be due to the
change of gene expression in cells of the skin or due to infiltration of
donor lymphocytes. Non-infiltrating or non-attaching donor
lymphocytes were washed off before freezing of the skin explants
and therefore would not contribute significantly to the results.
Infiltrating lymphocytes were rarely seen in skin explants by
histological analysis (data not shown). To further determine T cell
infiltration at the RNA level, we analyzed the expression of the CD3
zeta chain in qRT-PCR. Cd3z expression was found to be up-
regulated in comparison to syngeneic controls and medium controls
(Fig. 4A). The expression of most tested genes showed no
correlation with Cd3z mRNA levels (Fig. 4B). Only two of the
genes analyzed in qRT-PCR (Ly6g6e and Olr1) showed a moderately
positive correlation (r.0.50) with the Cd3z expression level
(Fig. 4B). Importantly, Ly6g6e was down- and not up-regulated in
allogeneic skin explants. The expression levels of three up-regulated
genes (Psmb8, Aif1, and Lst1) were even negatively associated with
Cd3z expression (Fig. 4B). Thus, of the tested genes only the
increase of Olr1 expression may be formally explained by infiltrating
T cells. However, Olr1 has not been described to be expressed in T
cells. Therefore, infiltration of skin explants with T cells is unlikely to
explain the observed gene expression changes.
Analysis of microarray results by qRT-PCR in independent
skin explant samples
Next we determined the expression of 10 selected genes in an
independent set of skin explant assays. Skin explants derived from BN
(RT1n) and LEW.1N (RT1n) rats were co-cultured with pre-stimulated
allogeneic lymphocytes from rats with minor (BN lymphocytes and
LEW.1N skin), major (LEW.1A [RT1a] or LEW.1AV1 [RT1av1]
lymphocytes and LEW.1N skin), or minor and major histoincompat-
ibility (PVG lymphocytes [RT1c] and BN skin or LOU/C [RT1u]
lymphocytes and LEW.1N skin). Skin samples cultured with syngeneic
lymphocytes (BN or LEW.1N) or cultured in medium only served as
controls. The GVHR grading obtained in these experiments is shown
in Figure 5. The general regulation of the selected genes during
GVHR was reproduced in this second experimental set when
compared to skin explants exposed to syngeneic lymphocytes and also
to samples cultured in medium only (Fig. 6). Aif1 and Lst1 were the
most consistently up-regulated genes in skin explants with minor,
major, and minor plus major histoincompatibility. The samples with
minor plus major histoincompatibility showed the highest variation in
gene regulation (Fig. 6). However, these samples were also most
heterogeneous in the GVHR grading (Fig. 5). Therefore, we analyzed
Table 1. The 20 most strongly regulated non-MHC/non-NKC genes in allogeneic skin explants compared to syngeneic controls as
revealed by the microarray experiment.
gene log2-fold change adjusted p-value gene description
LOC685020 8.18 0.0100 paired immunoglobin-like type 2 receptor alpha
Ptpns1l3 6.36 0.0100 protein tyrosine phosphatase, non-receptor type substrate 1-like 3
Fcgr3a 5.24 0.0100 Fc fragment of IgG, low affinity IIIa, receptor
Nat8 5.14 0.0100 Rattus norvegicus endogenous retrovirus mRNA, partial sequence [AY212271]
Ccl9 4.16 0.0100 chemokine (C-C motif) ligand 9
XM_226926 3.92 0.0149 Rattus norvegicus similar to protein tyrosine phosphatase, non-receptor type
substrate; brain immunological-like with tyrosine-based motifs (LOC310212)
Hck 3.87 0.0100 hemopoietic cell kinase
Trem2 3.78 0.0100 triggering receptor expressed on myeloid cells 2
Ccl6 3.71 0.0100 Rattus norvegicus chemokine (C-C motif) ligand 6
Cd36 3.57 0.0100 CD36 antigen
Igf1 3.23 0.0100 insulin-like growth factor 1
Ctss 3.15 0.0100 cathepsin S
Gzmc 3.11 0.0373 granzyme C
LOC100048479 2.97 0.0373 one cut domain, family member 1
Plscr1 2.83 0.0100 phospholipid scramblase 1
Nfe2 2.74 0.0149 nuclear factor, erythroid derived 2
Prg4 2.74 0.0149 proteoglycan 4
Spic 2.68 0.0278 Spi-C transcription factor
Fcgr2b 2.62 0.0100 Fc receptor, IgG, low affinity IIb
LOC498277 2.61 0.0100 similar to Low affinity immunoglobulin gamma Fc region receptor III precursor
doi:10.1371/journal.pone.0016582.t001
Table 2. Proportion of regulated genes as indicated by the
gene expression profiling experiment.
region
analyzed
genes regulated1 up-regulated
down-
regulated
MHC 224 11 (4.9%) 10 (4.5%) 1 (0.4%)
NKC 43 6 (14.0%) 6 (14.0%) 0 (0%)
others 6342 168 (2.6%) 93 (1.5%) 75 (1.2%)
1Only those genes that were both significantly (p,0.05) and strongly (log2-fold
change $1 or #21) regulated were taken into account for this comparison.
doi:10.1371/journal.pone.0016582.t002
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the gene regulation dependent from the GVHR grading in samples
from both experimental sets.
Regulation of selected MHC and NKC genes during GVHR
The expression of 7 MHC and 3 NKC genes was evaluated in
the skin explant samples showing grade I, II, III or IV GVHR
(Fig. 7). To provide an even more accurate comparison of the
different genes in this evaluation of the data, the relative changes
of gene expression levels were calculated using a mathematical
model for relative quantification of real-time PCR data which
takes into account variations in the amplification efficiencies of
different primer pairs [24]. When compared to skin explants
exposed to syngeneic lymphocytes or to medium controls, the
genes Aif1, Lst1, Olr1, and Ly49i9 were consistently up-regulated.
Ly6g6e was down-regulated in some but not all comparisons. The
expression of Aif1, Lst1 and Ly49i9 was found to be increased in all
GVHR grades. The extremely high up-regulation of Ly49i9
encoding an NK receptor in comparison to medium controls
might be explained by complete absence of NK cells in normal
skin biopsies and infiltration of few NK cells during GVHR. When
the gene expression was compared to freshly frozen healthy skin,
the principal findings were confirmed. Interestingly, Olr1 was up-
regulated mainly in grade II and III GVHR samples when
compared to syngeneic control skin explants and healthy skin.
Thus, this gene could be a marker of intermediate grade GVHR.
Regulation of selected MHC and NKC genes during GVHD
Next, we wanted to know whether the genes found to be
differentially expressed in GVHR in skin explant assays were also
regulated in vivo in GVHD. For this purpose we analyzed skin
samples from BN rats that were transplanted with bone marrow
from PVG rats and developed acute GVHD. The analyzed skin
samples showed in histology a grade I or grade II GVHD. The
results of qRT-PCR for 7 MHC genes and 3 NKC genes are
shown in Figure 8. The strongest up-regulation in GVHD-
affected skin was observed for RT1-DMb, Aif1, Lst1, and Olr1.
Thus, most genes that were found to be regulated in GVHR in
skin explants were also regulated in GVHD-affected skin.
However, the Ly49si1 gene that was up-regulated consistently in
allogeneic skin explants showing GVHR of grade II and above
appeared to be down-regulated in GVHD. Compared to the skin
explant samples, also the Ly49i9 gene was only moderately up-
regulated in grade II GVHD samples from transplanted rats.
Regulation of selected MHC and NKC genes during GVHR
in human skin explant assays
Finally, we explored the regulation of the identified genes
during GVHR in human skin explant assays. We determined the
expression of those genes for which human homologues exist. At 1,
2 and 3 days of co-culture with alloreactive lymphocytes skin
samples of one donor were taken and analyzed in comparison to
parallel samples cultured in medium only. At day 1 a GVHR of
grade I was observed that increased to grade II at day 2 and grade
III at day 3. We determined the expression of 15 MHC and 1
NKC gene by qRT-PCR (Table 3). Of these 16 genes 12 (75%)
were regulated at least in one skin explant sample in the way
predicted by the results of the rat expression profiling experiments
(Table 4). Three genes TAP1, PSMB8, and UBD were up-
regulated in all 3 human skin explant samples. The genes C2,
FLI13158, and OLR1 were regulated in 2 of the 3 samples as
predicted by the rat experiments. In addition, we determined the
expression of 153 non-MHC/non-NCR genes that were identified
to be regulated in rat skin explant assays. Also of these genes 105
(69%) were regulated in at least one of the human skin explant
samples in accordance with the results obtained in the rat model
(Table 4). These results suggest that the rat model of the skin
explant assay can reliably predict gene expression changes that
occur also in human skin explant assays during GVHR.
Discussion
We aimed to identify genes that are regulated during GVHR in
the skin explant assay because these genes could be involved in the
pathophysiology of GVHR and contribute to the genetic risk of
GVHD. Special attention was given to genes encoded within the
MHC region for the following reasons: Firstly, evidence has been
presented that further risk genes for GVHD in addition to MHC
class I and class II genes are present in this region [12]. Secondly,
those genes cannot easily be identified by genetic linkage analysis
alone due to the strong linkage disequilibrium with MHC class I
and class II genes so that expression profiling could be a
worthwhile alternative approach. Thirdly, we wanted to focus in
this initial study on a fully characterized genomic region of special
immunological importance rather than to follow a whole genome
expression profiling approach. Importantly, 39% of the BN rat
MHC genes (RT1n haplotype) annotated by Hurt and colleagues
[16] were at the time point of array construction not represented
Figure 4. Analysis of T cell infiltration in skin explants. (A) Analysis of Cd3z gene expression in the same samples as shown in Fig. 3. (B)
Correlation of Cd3z and other gene expression levels (DDct values for allogeneic skin explants minus syngeneic controls) in these samples. Pearson’s
correlation coefficients (r) and the p-values for the corresponding tests are given above the diagrams. In brackets Spearman’s correlation coefficients
(r) and the p-values for the corresponding tests are shown.
doi:10.1371/journal.pone.0016582.g004
Figure 5. Induction of a GVHR in a second series of BN (filled
circles) and LEW.1N (open circles) rat skin explants. Skin explants
were co-cultured with pre-stimulated allogeneic lymphocytes from rats
with a minor (BN lymphocytes and LEW.1N skin), major (LEW.1A (RT1a)
or LEW.1AV1 (RT1av1) lymphocytes and LEW.1N skin), or a minor and
major histoincompatibility (PVG lymphocytes (RT1c) and BN skin or
LOU/C (RT1u) lymphocytes and LEW.1N skin). A summary of the
histological GVHR grading of skin samples cultured in medium alone,
together with syngeneic BN or LEW.1N lymphocytes, and together with
allogeneic lymphocytes is given.
doi:10.1371/journal.pone.0016582.g005
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Figure 6. Verification of gene regulations observed in the microarray experiment by qRT-PCR in an independent set of 17 skin
explant assays. Three samples were derived from skin explant assays with minor (upper panel), 5 with major (middle panel), and 9 with minor and
major histoincompatibility (lower panel). The GVHR grading for these samples is shown in Fig. 5. The expression of 7 MHC and 3 NKC was analyzed
by qRT-PCR. The DDct value, i.e. Dct (Gapdh – gene of interest) of the allogeneic skin explant samples minus mean of Dct (Gapdh – gene of interest) of
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in the Agilent database and therefore not represented on the
Agilent whole rat genome array. In addition to the MHC region,
genes of the NKC region were included because this region
encodes Ly49 genes and their products can function as receptors
for the numerous MHC class Ia and Ib gene products encoded in
the MHC [17].
A higher percentage of MHC genes and NKC genes than genes
in other regions of the genome were found to be regulated in the
allogeneic skin explants compared to skin samples co-cultured with
syngeneic lymphocytes. Of the 25 MHC genes found to be
significantly regulated (p,0.05), 5 are known to be involved in
antigen processing and presentation. Besides two of three MHC
class Ia genes in the BN strain (RT1-A1 and RT1-A2) that present
peptides to cytotoxic T lymphocytes (CTL), the genes Tap1 and
Psmb8, encoding a subunit of the antigen transporter and a subunit
of the immunoproteasome (also known as LMP7), were found to
be up-regulated. RT1-DMb encodes a homologue of HLA-DMB, a
chaperone in the MHC class II presentation pathway. Further-
more, non-classical MHC class Ib genes (RT1-CE2, RT1-CE3,
RT1-CE5, RT1-CE8, RT1-CE10, RT1-CE16, RT1-T24-4, RT-
BM1) were up-regulated during GVHR in the skin explants. The
function of the RT1-C/E/M class I genes is not well defined. It is
known that they can become targets of CTL [25] and function as
ligands for activating or inhibitory NK receptors [17,18]. RT1-C/
E/M incompatibility has been shown to induce skin and pancreas
graft rejection [26] and to modulate the fate of MHC class II-
mismatched heart grafts [27]. The RT1-T24-4 gene belongs to a
family of genes that was originally identified as pseudogenes in the
haplotype r21 [28]. In the RT1n haplotype all four family members
are presumably functional [16]. However, their actual function has
not been experimentally demonstrated so far. The RT-BM1 (RT1-
S3) gene is assumed to be orthologous to the mouse H2-T23 gene
[29,30], which encodes the Qa-1 molecule. This is a functional
homologue of HLA-E, which presents leader peptides of MHC
class I molecules to the inhibitory NK receptor CD94/NKG2A
[31]. Interestingly, its expression can vary substantially depending
on the RT1 haplotype [14]. It has to be noticed that no human/
rat orthology can be established for the class I genes in the various
class I clusters. Therefore, with respect to class I genes, the rat
cannot serve as a model for the HLA complex. However, the non-
class I genes are clearly orthologous [15,16].
In addition to Tap1, Psmb8, and RT1-DMb, 12 further non-class
I MHC genes were found to be regulated in the rat skin explant
assays, some of them also involved in the immune response, such
as the complement component C2, while such a role is strongly
assumed for other genes. The allograft inflammatory factor 1
(Aif1), was cloned from chronically rejecting rat cardiac allografts
[32] and it was also found in transplanted human hearts [33].
Persistent expression of AIF-1 is associated with the development
of a cardiac allograft vasculopathy [34]. The expression of AIF-1 is
mostly limited to the monocyte/macrophage lineage, and can be
augmented by interferon (IFN)-c. The specific function of the
leukocyte specific transcript 1 (Lst1) gene is not known, although its
strong expression in dendritic cells and functional data suggest an
immunomodulatory role [35]. The expression of human LST1,
specifically of splice variants encoding soluble isoforms, was
increased in rheumatoid arthritis-affected blood and synovium and
was up-regulated in response to IFN-c [36]. The immediate early
response 3 (Ier3) gene is stress-inducible and is involved in the
regulation of cell death and oncogenesis [37]. The protein (also
known as IEX-1 or IEX-1L) functions in the protection of cells
from Fas or TNF-a-induced apoptosis [38]. However, it increases
the rate of apoptosis in ultraviolet B irradiated keratinocytes [39].
Distinct domains of the proteins were described to be responsible
for pro and anti-apoptotic activities of the protein [40]. The
diubiquitin gene (Ubd) has been shown to be expressed in rat
lymphoblasts, thymus, and testis [41]. In the mouse it is expressed
in dendritic cells and B cells, is inducible by IFN-c, and can cause
apoptosis [42]. The protein (also known as FAT10) provides an
ubiquitin-independent signal for proteasomal degradation [43]. It
has been suggested to participate in antigen processing [44], but its
expression did not affect MHC class I expression or antigen
presentation [42]. In view of the reported roles of these genes in
the immune response, a direct involvement in GVHD is
conceivable.
For the other regulated MHC genes an involvement in immune
functions has not been established so far. Spr1 (or Psors1c2) is the
psoriasis susceptibility 1 candidate 2 gene and was found to be
expressed in the thymus of rats [41]. Its human homologue is
expressed in normal and psoriatic skin and has been suggested to
confer susceptibility to psoriasis [45]. The function of the gene
product is not known so far. G18 (Gpsm3) is an activator of G-
protein signaling [46]. Pbx2 encodes an ubiquitously expressed
transcriptional activator [47]. The Ly6g6e gene belongs to the
lymphocyte antigen 6 (Ly-6) superfamily that encodes proteins
attached to the cell surface by a glycosylphosphatidylinositol (GPI)
anchor that is directly involved in signal transduction [48]. Mouse
Ly6g6e was found to be highly expressed at the leading edges of
cells, on filopodia, which are normally involved in cell adhesion
and migration [49]. The mitochondrial ribosomal protein S18B
(Mrsps18b) gene encodes a 28S subunit protein that belongs to the
ribosomal protein S18P family. The functions of the HLA-B
associated transcript 5 (Bat5) and Fij13158 (or RGD1303066) genes
have not been characterized so far. Some MHC genes, such as Tnf
encoding the tumor necrosis factor alpha or the heat shock protein
70 genes Hspa1b and Hspa1a, which were expected to be up-
regulated [22,50], were actually not found to be significantly
regulated in the rat skin explants. Thus, it is possible that some
MHC genes that can be regulated during GVHR were not
identified in our microarray experiments.
Many of the up-regulated MHC genes are inducible by IFN-c a
type II cytokine that is primarily secreted by activated T and NK
cells. Several studies have demonstrated an increased level of IFN-
c in the early phase of GVHD [51,52]. Therefore, this cytokine
might be highly important for the regulation of the expression of
MHC genes during GVHR.
We also included the NKC region in the expression profiling
which harbors the Ly49 genes that encode NK receptors of the
killer cell lectin-like receptor type [19] and some of these have
been shown to interact with both MHC class Ia and Ib molecules
[17,18]. In contrast to the MHC region, no reference sequence has
been published for the NKC region of the rat. Therefore, 20 genes
that were recently assigned to this region in the assembly RGSC
v3.4 [53] were not represented on the array. However, for most of
them no function associated with the immune system has been
reported. Interestingly, only Ly49 receptor genes which have an
the corresponding control samples (BN or LEW.1N, respectively), was calculated. The control samples were either skin explant samples exposed to
syngeneic lymphocytes (syngeneic control) or skin explant samples cultured in medium only without added lymphocytes (medium control) and their
GVHR grading is also shown in Fig. 5. The means of the DDct values plus SEM are shown. A positive value indicates an up-regulation of gene
expression in the allogeneic samples.
doi:10.1371/journal.pone.0016582.g006
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Figure 7. Analysis of MHC and NKC gene regulation in skin explants exposed to pre-stimulated allogeneic lymphocytes depending
on GVHR grading. The expression of 7 MHC and 3 NKC was analyzed by qRT-PCR. The relative changes of gene expression levels were calculated
using a mathematical model for relative quantification of real-time PCR data which also takes into account variations of the amplification efficiencies
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ITIM motif in their cytoplasmic region were up-regulated in the
allogeneic skin explant assays. This includes also the LOC690045
gene which encodes an immunoreceptor similar to Ly49si1. It is
not clear whether one of these gene products interacts with the
MHC class Ib molecules that we found to be up-regulated. Ly49
receptors are normally present mainly on NK cells and the skin
explants harbored few leukocytes. However, skin resident
lymphocytes can become activated in human skin explant assays
[54]. Although few NK cells infiltrating a tissue that normally does
not contain these cells might cause a drastic relative change in the
presence of Ly49 transcripts, the possibility should not be dismissed
that other cells may express the receptors under pathological
conditions. The role of NK cells for GVHR in skin explants needs
to be further explored. In general NK cells are assumed to prevent
GVHR, improve engraftment and to exert strong graft-versus-
leukemia effects without causing GVHD [55].
In the NKC region we found one non-Ly49 gene to be
regulated. The Olr1 gene encodes a receptor protein which
belongs to the C-type lectin superfamily. The protein (also known
as LOX-1) binds, internalizes and degrades oxidized low-density
lipoprotein, which induces vascular endothelial cell activation and
dysfunction, resulting in pro-inflammatory responses, pro-oxida-
tive conditions and apoptosis [56]. In addition, it acts as a receptor
for extracellular heat shock protein 70 on dendritic cells. Binding
and internalization of heat shock protein 70/peptide complexes
channels peptides into the MHC class I presentation pathway [57].
Thus, the protein is involved in antigen cross-presentation to naive
T cells.
In addition to the MHC and NKC region genes, 168 further
genes were significantly regulated in allogeneic skin explants.
Many of them also have immunological functions and need to be
analyzed in more detail in subsequent studies.
The results obtained in the MHC and NKC gene expression
profiling experiment were confirmed in most tested cases by qRT-
PCR on the skin explant samples. Some genes, e.g. Aif1 and
Ly49i9, appeared to be up-regulated even in grade I GVHR. Olr1,
in contrast, was up-regulated predominantly in grade II and III
GVHR in all comparisons. Importantly, several of the MHC and
NKC genes that were identified to be regulated in the skin explant
assays, including Aif1, Lst1, and Olr1, were also regulated in the
GVHD affected skin of transplanted animals. Thus, the skin
explant assay can model GVHD not only histologically but also
with respect to gene regulation. However, the up-regulation of the
tested Ly49 genes (Ly49si1 and Ly49i9) that were observed in the
skin explant was not clearly confirmed in the GVHD-affected skin
of transplanted rats. Skin lesions from transplanted animals are
likely to be more heterogeneous with respect to the dynamics of
the pathophysiological process, including infiltration of NK cells,
than skin explant samples, and this may contribute to the variation
in results. In addition, variability between microarray and qRT-
PCR results might be partly attributed to the fact that in qRT-
PCR experiments the results were normalized to only one control
gene. In contrast, many genes were used in the microarray
experiments for data normalization. More control genes could be
employed for data normalization in qRT-PCR experiments in
further validation studies to reduce this source of variability [58].
In an exploratory experiment, we analyzed the expression of
169 genes with human homologues, including the respective MHC
and NKC region genes, identified in the rat in human skin explant
samples. These human skin explants were cultured for 1, 2, or 3
days resulting in GVHR of grades I, II, and III, respectively.
Notably, 69% of all tested human genes were found to be
regulated in at least one of these human samples as predicted by
the results of the rat expression profiling experiments. 21%, i. e. 36
of different primer pairs [24]. The means plus SEM are shown. A value .1 indicates an up-regulation of gene expression in the allogeneic samples.
The control samples were either skin explant samples exposed to syngeneic lymphocytes (syngeneic control, upper panel), skin explant samples
cultured in medium only (medium control, mean panel), or freshly frozen healthy skin samples (healthy skin control, lower panel).
doi:10.1371/journal.pone.0016582.g007
Figure 8. Analysis of MHC and NKC gene regulation in GVHD skin lesions from transplanted animals. BN (RT1n) rats were transplanted
with bone marrow of PVG (RT1c) rats. Rats that developed acute GVHD were scarified and skin lesions with signs of GVHD were obtained for RNA
preparation and histology. The expression of 7 MHC and 3 NKC was analyzed by qRT-PCR using the B2m gene as reference. The relative changes of
gene expression levels were calculated [24]. The means plus SEM are shown for skin lesion with grade I and grade II GVHD. A value .1 indicates an
up-regulation of gene expression in the allogeneic samples. The control samples were freshly frozen skin samples from healthy BN rats (n = 7).
doi:10.1371/journal.pone.0016582.g008
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of the tested genes, were regulated in all 3 human skin explant
samples in accordance with the rat model, but this regulation
varied depending on the GVHR grade and the time course of the
skin explant assay. Although we only validated these genes on 3
samples, the unexpectedly high concordance rate between the
results of rat and human skin explant assays strongly suggests that
the rat skin explant assay is an informative model for human
GVHR and possibly GVHD. However, the variability of results in
these few human skin explant samples also indicates that it is
unlikely to find a single gene that can serve as universal marker for
GVHR. It is more conceivable that patterns of gene expression
could contribute to an improved diagnosis and classification of
GVHR.
Interestingly, for some of the genes that we found to be
regulated in GVHR and GVHD in the rat, the human
homologues are polymorphic and disease associations of gene
polymorphisms have been described. These include HLA-DMB
[59], C2 [60], AIF1 [61], SPR1 [45], and possibly UBD [62].
Therefore, these genes are especially interesting candidates of
further non-class I/class II HLA genes that might confer an
increased genetic risk of GVHD after HSCT depending on the
genotype. In addition, the OLR1 gene in the NKC is polymorphic
and polymorphisms of this gene have been associated with
atherosclerosis, myocardial infarction [63], and Alzheimer’s
disease [64].
Table 4. Proportion of concordantly regulated in MHC, NKC, and genes encoded in other regions in human skin explant assays in
comparison to rat skin explant assays.
region
analyzed human
genes mRNA not detected
concordantly regulated in human skin explant
assays in comparison to rat skin explant assays not concordantly regulated
3/3 2/3 1/3 0/3
MHC 15 1 (7%) 3 (20%) 2 (13%) 6 (40%) 3 (20%)
NKC 1 0 (0%) 0 (0%) 1 (100%) 0 (0%) 0 (0%)
others 153 18 (12%) 33 (22%) 31 (20%) 41 (27%) 30 (20%)
doi:10.1371/journal.pone.0016582.t004
Table 3. Regulation of MHC and NCR candidate genes in human skin explants.
regulation in rat skin explant
assays (expression profiling) regulation in human skin explant assay concordance rate
day 1
(GVHR I)
day 2
(GVHR II)
day 3
(GVHR III)
MHC region
HLA-DMB q1 - q - 1/3
TAP1 (q) q q q 3/3
PSMB8 q q q q 3/3
G18 (GPSM3) q n.d. n.d. n.d.
PBX2 (q) Q n.d. q 1/3
C2 q q q Q 2/3
LY6G6E Q n.d. q n.d. 0/3
BAT5 Q - - - 0/3
AIF1 q Q q Q 1/3
LST1 q - q n.d. 1/3
SPR1 (PSORS1C2) q - - q 1/3
IER3 q Q q - 1/3
FLI13158 (Q) Q Q - 2/3
MRPS18B (q) Q Q Q 0/3
UBD q q q q 3/3
NCR region
OLR1 q q q n.d. 2/3
1Explanation of symbols:
q up-regulated mRNA expression level (log2-fold change $1).
Q down-regulated mRNA level (log2-fold change #21).
- unchanged mRNA expression level (log2-fold change .-1 and ,1).
(q) significant (p,0.05) but moderate up-regulation (log2-fold change ,1) of mRNA expression level in the rat expression profiling experiment.
(Q) significant (p,0.05) but moderate down-regulation (log2-fold change .21) of mRNA expression level.
n.d. no mRNA detected.
doi:10.1371/journal.pone.0016582.t003
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Several laboratory tests have been assessed for their ability to
predict the risk of GVHD in patients. The skin explant assay has a
predictive value of about 80% when cyclosporine alone is used for
GVHD prophylaxis [65]. A gene expression analysis of selected
genes may help to further improve the predictive value of the
assay. Pre-transplant gene expression profiling of donor peripheral
blood mononuclear cells (PBMC) has recently been shown to be a
useful tool to predict the risk of GVHD [66]. Post transplant
differences in the gene expression profile of PBMC of patients with
acute [67,68] and chronic GVHD [69] compared to non-GVHD
samples have been described. The general gene expression profile
of target tissues of GVHD has been previously analyzed only in
mouse models of cutaneous and hepatic GVHD [70,71]. Some of
the genes identified in these studies overlap with our results. In
cutaneous GVHD the MHC genes Tap1, Psmb8, and Ubd were
also found to be up-regulated [71]. In hepatic GVHD the
expression of Tap1, Psmb8 (Lmp7), H2-DMb, Aif1, and Ubd (Fat10)
was increased [70].
In conclusion, the MHC gene expression profiling approach in
the rat skin explant assay identified a number of non-class I/class
II genes that might contribute to the MHC-associated risk of
GVHD following HSCT. These genes could be directly involved
in the pathophysiology of GVHD or serve as molecular markers
for GVHD and GVHR. The possibility should not be dismissed,
however, that these marker genes could indicate that protective
pathways are induced which modulate tissue damage during
inflammation. Moreover, their human homologues may be useful
for risk assessment, diagnosis, and as potential targets for therapy
of GVHD in patients.
Materials and Methods
Rat strains
For the skin explant assays, rats of the inbred strains LEW.1N
(RT1n), LEW.1A (RT1a), LEW.1AV1 (RT1av1), LOU/C (RT1u),
and BUF (RT1b) were bred in the central animal facility of the
Medical Faculty of the University of Go¨ttingen. Rats of the strains
PVG/OlaHsd (RT1c) and BN/RijHsd (RT1n) were purchased
from Harlan Winkelmann (Borchen, Germany). Animals between
10 and 20 weeks of age were used for the experiments. For
transplantation experiments, PVG rats of the RT7.2 allotype
(allelic variant RT7b), originally obtained from Harlan OLAC,
UK), were bred at the animal facility of the University of Oslo and
BN rats were purchased from Harlan.
Rat skin explant assays
Rat skin explant assays were performed as previously described
in detail [22]. Briefly, mononuclear cells were obtained from rat
spleens. Responder and irradiated (25 Gy) stimulator splenocytes
were co-cultured in a MLR and the proliferation of responder
lymphocytes was tested by [methyl-3H]-thymidine (Amersham,
Braunschweig, Germany) incorporation. The stimulation index
was calculated as described [22]. After 7 days 106 responder
lymphocytes were added to freshly obtained skin samples from the
stimulator strain that were cultured in 200 ml NaHCO3-buffered
Dulbecco’s modified Eagle’s medium (DMEM; Biochrom) sup-
plemented with 3% normal rat serum, 2 mM L-glutamine, 1 mM
sodium pyruvate, and antibiotics in round-bottomed microtitre
plates (Sarstedt, Nu¨mbrecht, Germany). The skin samples were
excised from the paws of rats after washing with 70% ethanol. The
subcutaneous fat tissue was removed and the samples were
trimmed to a size of approximately 1.561.5 mm. Skin samples
cultured in medium only and samples co-cultured with lympho-
cytes from a ‘‘syngeneic MLR’’ were used as controls. After 3 days,
the skin explants were washed with N-2-hydroxyethylpiperazine-
N’-2-ethanesulfonic acid (HEPES)-buffered DMEM and snap
frozen in liquid nitrogen and stored at 280uC for RNA
preparation. Parallel samples were fixed in 10% neutral-buffered
formalin, sectioned, and stained with hematoxylin and eosin
(H&E). The histological evaluation of the skin explants was
performed blind by an expert histopathologist (L.S.) based on the
grading system described by Lerner [72].
Human skin explant assays
PBMC and skin samples were obtained from healthy volunteers
or autologous HSCT patients following written informed consent
and approval from the North Tyneside Research Ethics
Committee. Buffy coat from normal blood donations were
obtained from Newcastle National Blood Service with consent.
Skin explant assays were performed as previously described with
slight variations [73]. In brief, 16107 responder PBMC from a
healthy volunteer were cultured with an equal number of
irradiated PBMC from a bone marrow transplant patient, in
10 ml complete medium (RPMI 1640 supplemented with
antibiotics, 2 mM L-glutamine and 10% heat inactivated human
AB serum) in a 25 cm2 flask. After 7 days of culture, MLR primed
lymphocytes were washed and resuspended in complete medium
supplemented with 20% heat inactivated autologous (patient)
serum and co-cultured with patient skin explants at a cell
concentration of 16106 cells/well in a volume of 200 ml/well.
Standard 4-mm punch skin biopsy specimens were obtained pre-
transplant from the patients. Under sterile conditions the skin
biopsies were trimmed of excess dermis and divided into 8 to 10
sections of equal size. Each section was cultured separately with
either MLR-primed responder cells or culture medium in 96-well
round-bottomed microtitre plates. After 1, 2 or 3 days of co-
culture skin explants were fixed in 10% buffered formalin,
sectioned and stained with H&E. The histopathological evaluation
[72] of the skin explants was performed blindly and independently
by at least 2 assessors. Grade I histopathological damage in skin
biopsies was regarded as background which would be observed in
medium control or autologous cell/autologous MLR controls. All
biopsies presenting histopathological damage of grade II or above
were regarded as positive.
Bone marrow transplantation
Transplantation experiments were approved by the Experi-
mental Animal Board under the Ministry of Agriculture of
Norway (ID 09.1514, 09.1515 and VIT 09.1512). Male PVG
(RT7b) rats served as bone marrow and lymph node donors.
Mononuclear bone marrow cells were purified by density gradient
centrifugation in Nycoprep 1.077A (Medinor ASA, Norway). The
cells were depleted of T cells by magnetic separation using anti-
CD5 (Ox19) and anti-ab T cell receptor (R73) antibodies
conjugated to pan-mouse IgG coated Dynabeads (Dynal Biotech
ASA, Norway). This procedure reduced the CD3+ T cell content
in the bone marrow from 3% to less than 0.3%. Male BN rats
were used as recipients. They were irradiated (9 Gy) and
subsequently received an i.v. injection of 306106 PVG.7b T
cell-depleted bone marrow cells. 14 days post transplantation,
1.56106 lymph node cells were injected i.v. to evoke GVHD. The
rats were regularly monitored for GVHD symptoms. Rats
suffering from irreversible GVHD were sacrificed and skin samples
were processed for RNA preparation and histology in parallel.
RNA preparation
RNA extraction was carried out using TRIZOL reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
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recommendations. Afterwards, the RNA samples were treated
with RQ1 RNase free DNase (Promega, Madison, WI, USA) for
20 min at 37uC in order to remove genomic DNA contamina-
tions. The RNA was then purified as described previously [22].
Quantity and quality of extracted RNA were controlled by
capillary electrophoresis using the Bioanalyzer 2100 (Agilent
Technologies, Santa Clara, CA, USA).
Microarray experiment
For the expression profiling, a custom-designed oligo DNA
microarray (Agilent) was used. The 15K microarray covered 224
MHC genes by 649 oligonucleotide probes and 43 NKC genes by
101 probes. These probes were spotted in triplicates. Further
probes representing 6342 genes were added mainly to allow for
data normalization. A two-color 1262 paired swap design [74]
using 24 arrays was applied, comparing RNA samples from 12
independent allogeneic and 12 independent syngeneic skin explant
assays. Aliquots of total RNA (200 ng) were used as starting
material. The ‘‘Low RNA Input linear Amplification Kit Plus, two
color’’ (Agilent, 5188-5340) and the ‘‘RNA Spike-In Kit’’ (Agilent,
5188-5279) were used for cDNA synthesis and in-vitro transcription
according to the manufacturer’s recommendations. Quantity and
dye incorporation rates of the amplified cRNAs were determined
using the NanoDrop ND-1000 UV-VIS Spectrophotometer
version 3.2.1 (NanoDrop Technologies, Wilmington, DE, USA).
Afterwards, 300 ng aliquots of Cy3 and Cy5-labeled cRNAs from
syngeneic and allogeneic skin explant assays, respectively, were
mixed and hybridized to the microarrays. The hybridization was
performed for 17 hours at 10 rpm and 65uC. After washing, Cy3
and Cy5 intensities were detected by two-color scanning using a
DNA microarray scanner (Agilent, G2505B) at 5 micron
resolution. Scanned image files were visually inspected for
artifacts. The generated raw data were extracted using the Feature
Extraction 9.1 software (Agilent). The normalization of the raw
microarray data was done with a non-linear loess regression [75].
Differentially expressed genes were identified by an analysis of
variance (ANOVA) mixed effects model [74] using SAS PROC
MIXED. The resulting p-values were adjusted with the Benjamini-
Hochberg method to control the false discovery rate [76]. The
microarray data were generated conforming to the MIAME
guidelines and have been deposited in NCBI’s Gene Expression
Omnibus (accessible through GEO series accession number
GSE17928). For a general analysis of the gene expression data
the PANTHER (Protein ANalysis THrough Evolutionary Rela-
tionships) system [23] was used, which classifies genes by their
functions (www.pantherdb.org/tools/genexAnalysis.jsp). The mi-
croarray data were mapped to PANTHER molecular function
and biological process categories, as well as to biological pathways
[77].
Validation of rat candidate genes by quantitative real-
time PCR
To validate the expression change of candidate genes, qRT-
PCR assays were used. Specific primers for 10 MHC and 3 NKC
genes were designed (Table S4). To generate external standard
curves and to calculate the amplification efficiency of each primer
pair, a pool of 20 random cDNAs was amplified in serial 10-fold
dilutions [24]. The amplification reactions were carried out as
described previously [22] using an ABI 7500 Real-Time PCR
System. The data were analyzed with the ABI 7500 SDS software
(Applied Biosystems). As internal control, mRNA expression of
housekeeping genes Gapdh (Rn_Gapd_1_SG QuantiTect Primer
Assay QT00199633, Qiagen, Hilden, Germany) or B2m (Table
S4) were monitored. To normalize variations in the RNA
concentration in different samples, the ct values obtained in real-
time PCR for the genes were corrected by the ct-value obtained
for the housekeeping gene in the same sample (Dct = ct
housekeeping gene - ct gene of interest). For direct comparison
with microarray data, the relative changes of mRNA expression
were calculated using the DDct method (DDct = Dct sample of
interest – Dct control sample) [78]. For additional analyses, the
relative changes of gene expression levels were calculated using a
mathematical model for relative quantification of real-time PCR
data which takes into account variations of the amplification
efficiencies of different primer pairs [24].
Validation candidate genes in human skin explant assays
by quantitative real-time PCR
Validation of the rat candidate genes with human homologues
in the human skin explant assay was also done by qRT-PCR. For
this we used relative quantification using custom designed
Taqman low density array (TLDA) cards (Applied Biosystems),
each card contained 4 replicates of 95 unique genes and a control
gene, 18S. The qRT-PCR reactions were set up using Taqman x2
gene expression mastermix (Applied Biosystems), 50 ng RNA
equivalent of cDNA and the total volume adjusted to 200 ml with
nuclease free water (Quiagen). The TLDA cards were run on a
7900 qRT-PCR system (Applied Biosystems) using the TLDA
block and analysed using the RQ manager 1.2 software (Applied
Biosystems). The relative changes in RNA expression were also
calculated using the DDct method described above.
Statistical analyses not related to microarray experiments
Paired comparisons between experimental groups were per-
formed using the nonparametric Mann-Whitney U test. Pearson’s
and Spearman’s correlation coefficients were calculated to
determine the correlation between mRNA expression levels of
two genes. The statistical analyses were performed using
WinSTATH software.[79]
Supporting Information
Table S1 Expression profiling results of MHC genes. In
Table S1a, results for all 224 MHC genes are shown in their
chromosomal order [16]. The expression profiling results of BN
skin explant samples exposed to pre-stimulated allogeneic (PVG)
lymphocytes in comparison to those exposed to syngeneic (BN)
lymphocytes are given. The log2-fold changes and the fold
changes in gene expression are shown for every oligonucleotide
probe used. The adjusted p-values are indicated. Significant
(p,0.05) and strong (log2-fold change $1 or #21; i.e. fold
change $2 or #0.5) results are indicated in bold font. In addition,
the identification numbers of the probes on the arrays are given
(probe ID) together with the information whether these probes
were taken from the Agilent database or custom designed. Table
S1b contains the same information for all MHC genes for which
at least one probe indicated a significant alteration of gene
expression. In Table S1c, the data for those genes are
summarized that are considered to be regulated significantly
because either at least a single probe indicated a significant
(p,0.05) and strong (log2-fold change $1 or #21) regulation or
at least 50% of the gene probes indicated a significant (p,0.05)
regulation of gene expression.
(XLS)
Table S2 Expression profiling results of NKC genes. In
Table S2a, results for all 43 NKC genes investigated are
indicated in their chromosomal order (Klrg; Pzp to Csda). The
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expression profiling results of BN skin explant samples exposed to
pre-stimulated allogeneic (PVG) lymphocytes in comparison to
those exposed to syngeneic (BN) lymphocytes are given. The log2-
fold changes and the fold changes in gene expression are shown for
every oligonucleotide probe used. The adjusted p-values are
indicated. Significant (p,0.05) and strong (log2-fold change $1 or
#21; i.e. fold change $2 or #0.5) results are indicated in bold
font. In addition, the identification numbers of the probes on the
arrays are given (probe ID) together with the information whether
these probes were taken from the Agilent database or custom
designed. Table S2b contains the information for all NKC genes
for which at least one probe indicted a significant alteration of
gene expression. In Table S2c, the data for those genes are
summarized that are considered to be regulated significantly
because either at least a single probe indicated a significant
(p,0.05) and strong (log2-fold change $1 or #21) regulation or
at least 50% of the probes indicated a significant (p,0.05)
regulation of gene expression.
(XLS)
Table S3 Regulated non-MHC non-NKC genes. The
expression profiling results of non-MHC non-NKC genes are
given for those genes that were both significantly (p,0.05) and
strongly (log2-fold change $1 or #21; i.e. fold change $2 or
#0.5) regulated. The log2-fold changes and the fold changes in
gene expression are shown. The adjusted p-values are indicated.
For 20 of these genes at least two different probes were present on
the array. In 8 cases (indicated by gene symbols in bold) the second
probe indicated the same strong and significant regulation and in 7
further cases (indicated by gene symbols in italics) the second
probe indicated a regulation with borderline amplitude or
significance. In 5 cases (indicated by gene symbols in blue font)
the results of the two probes for a gene did not confirm each other.
Furthermore, the identification numbers of the probes on the
arrays are given (probe ID) together with the information whether
these probes were taken from the Agilent database or custom
designed.
(XLS)
Table S4 Primer sequences used for mRNA expression
analysis.
(DOC)
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